.png){kind=logo}
Our Research
NatureCeuticals is a clinical-stage botanical pharmaceutical company dedicated to developing evidence-based botanical medicines for oncology and chronic diseases. Our research spans the entire development pathway—from drug discovery and preclinical pharmacology to international multicentre clinical trials. Our state-of-the-art research laboratories integrate advanced pharmaceutical sciences, molecular biology, pharmacology, and translational medicine to accelerate the development of innovative botanical therapeutics. Through collaborations with leading universities, research institutes, and close to 20 major hospitals worldwide, we are transforming promising natural compounds into clinically validated healthcare solutions.
Cancer Research
Leading Innovation in Botanical Oncology Research
For nearly two decades, NatureCeuticals has been a leader in botanical oncology research, developing evidence-based botanical therapeutics for cancer supportive care and adjunctive treatment. Our multidisciplinary research integrates pharmaceutical sciences, molecular pharmacology, translational medicine, and clinical oncology to address critical unmet needs in cancer care.
Today, NatureCeuticals is one of Malaysia's leading clinical-stage botanical oncology research companies, with an extensive portfolio of laboratory, preclinical, and international clinical research. Our scientists investigate botanically derived compounds with anti-cancer mechanisms including anti-angiogenic, antioxidant, anti-inflammatory, immunomodulatory, and chemosensitising properties that may complement conventional cancer therapies.
Our translational research spans molecular and cellular studies, animal models, and multicentre human clinical trials, enabling promising discoveries to progress from the laboratory to real-world clinical applications through rigorous scientific evaluation.
NatureCeuticals has completed multiple clinical studies assessing its proprietary botanical formulations in patients undergoing chemotherapy. Our flagship product, Nuvastatic™, has demonstrated clinically meaningful improvements in cancer-related fatigue, quality of life, pain, sleep quality, psychosocial wellbeing, and oxidative stress in randomised controlled trials involving hundreds of cancer patients.
Building on these results, we are conducting large international multicentre clinical trials in advanced metastatic breast and colorectal cancer. These studies are evaluating Nuvastatic™ alongside standard chemotherapy to improve treatment tolerance, reduce cancer-related fatigue, enhance quality of life, and assess clinical outcomes.
Our preclinical oncology programme continues to investigate breast, colorectal, pancreatic, glioblastoma, and other solid tumours, focusing on novel therapeutic mechanisms, biomarkers, tumour microenvironment modulation, angiogenesis inhibition, and combination strategies with established anti-cancer therapies.
Supported by collaborations with leading oncologists, universities, research institutions, and hospitals across multiple countries, NatureCeuticals remains committed to advancing clinically validated botanical medicines through rigorous scientific research, international clinical development, and evidence-based innovation.
Vision Care
Our lead product, Nuvastatic™, has completed Phase III evaluation for cancer-related fatigue in breast cancer patients undergoing chemotherapy and is now being studied alongside standard chemotherapy in metastatic colorectal cancer and metastatic triple-negative breast cancer. With established hospital use in supportive care and a growing body of clinical, preclinical and patient evidence, Nuvastatic™ represents a broader approach to cancer care—supporting patients through treatment while investigating its potential to improve clinical outcomes.
Metabolic Diseases
NatureCeuticals is advancing the science of botanical medicines for metabolic health. Our research programmes focus on hypertension, diabetes, gout, hypercholesterolaemia, chronic kidney disease, kidney stones, and urinary tract infections. Combining advanced pharmaceutical research with evidence-based clinical development, we are creating innovative botanical therapeutics designed to address the underlying mechanisms of metabolic disease. Supported by rigorous laboratory research, preclinical studies, and clinical investigations, our mission is to deliver safe, scientifically validated solutions that improve long-term health and quality of life.
Respiratory Health and Infectious Diseases
Harnessing Botanical Science for Emerging Healthcare Challenges.
NatureCeuticals is expanding its research into respiratory and infectious diseases through the development of innovative botanical therapeutics with anti-inflammatory and immunomodulatory properties. Our research programme focuses on addressing diseases where excessive inflammation and immune dysregulation contribute significantly to disease severity and clinical outcomes.
As part of this programme, NatureCeuticals conducted a pilot clinical investigation evaluating one of its proprietary botanical formulations in patients with COVID-19. The study generated encouraging preliminary findings, supporting the product's potential role in promoting respiratory health and modulating inflammatory pathways, including interleukin-6 (IL-6), a key mediator associated with severe inflammatory responses. Building on these findings, NatureCeuticals is exploring the therapeutic potential of its botanical platform for other chronic respiratory conditions, including asthma, where persistent airway inflammation remains a major clinical challenge. Complementary laboratory and preclinical studies continue to investigate the product's anti-inflammatory, antioxidant, and immunomodulatory mechanisms that may contribute to improved respiratory health.Looking ahead, NatureCeuticals plans to expand its clinical research into selected infectious diseases of significant global and regional importance, including malaria and dengue fever, with the objective of developing scientifically validated botanical therapeutics that complement existing standards of care. Supported by advanced pharmaceutical research, translational science, and strategic collaborations with clinical and academic partners, NatureCeuticals remains committed to translating botanical innovation into evidence-based healthcare solutions for respiratory and infectious diseases.
Harnessing Botanical Science for Emerging Healthcare Challenges
NatureCeuticals is expanding its research into respiratory and infectious diseases through the development of innovative botanical therapeutics with anti-inflammatory and immunomodulatory properties. Our research programme focuses on addressing diseases where excessive inflammation and immune dysregulation contribute significantly to disease severity and clinical outcomes.
As part of this programme, NatureCeuticals conducted a pilot clinical investigation evaluating one of its proprietary botanical formulations in patients with COVID-19. The study generated encouraging preliminary findings, supporting the product's potential role in promoting respiratory health and modulating inflammatory pathways, including interleukin-6 (IL-6), a key mediator associated with severe inflammatory responses.
Building on these findings, NatureCeuticals is exploring the therapeutic potential of its botanical platform for other chronic respiratory conditions, including asthma, where persistent airway inflammation remains a major clinical challenge. Complementary laboratory and preclinical studies continue to investigate the product's anti-inflammatory, antioxidant, and immunomodulatory mechanisms that may contribute to improved respiratory health.
Looking ahead, NatureCeuticals plans to expand its clinical research into selected infectious diseases of significant global and regional importance, including malaria and dengue fever, with the objective of developing scientifically validated botanical therapeutics that complement existing standards of care.
Supported by advanced pharmaceutical research, translational science, and strategic collaborations with clinical and academic partners, NatureCeuticals remains committed to translating botanical innovation into evidence-based healthcare solutions for respiratory and infectious diseases.
As part of this programme, NatureCeuticals conducted a pilot clinical investigation evaluating one of its proprietary botanical formulations in patients with COVID-19. The study generated encouraging preliminary findings, supporting the product's potential role in promoting respiratory health and modulating inflammatory pathways, including interleukin-6 (IL-6), a key mediator associated with severe inflammatory responses. Building on these findings, NatureCeuticals is exploring the therapeutic potential of its botanical platform for other chronic respiratory conditions, including asthma, where persistent airway inflammation remains a major clinical challenge. Complementary laboratory and preclinical studies continue to investigate the product's anti-inflammatory, antioxidant, and immunomodulatory mechanisms that may contribute to improved respiratory health.Looking ahead, NatureCeuticals plans to expand its clinical research into selected infectious diseases of significant global and regional importance, including malaria and dengue fever, with the objective of developing scientifically validated botanical therapeutics that complement existing standards of care. Supported by advanced pharmaceutical research, translational science, and strategic collaborations with clinical and academic partners, NatureCeuticals remains committed to translating botanical innovation into evidence-based healthcare solutions for respiratory and infectious diseases.
Alzheimer's Disease and Neuronal Health
Advancing Botanical Therapeutics for Neurodegenerative Diseases
NatureCeuticals is actively investigating the therapeutic potential of its proprietary botanical platform for the prevention and management of neurodegenerative disorders. Our neuroscience research integrates molecular pharmacology, pharmaceutical sciences, and translational medicine to develop innovative botanical therapeutics targeting the complex biological mechanisms underlying progressive neurological diseases.
Extensive preclinical studies have evaluated standardized Orthosiphon stamineus formulations rich in bioactive phytochemicals, including rosmarinic acid and sinensetin. These compounds have demonstrated potent antioxidant, anti-inflammatory, and neuroprotective activities in experimental models, supporting their potential role in reducing oxidative stress, neuroinflammation, and neuronal injury—key pathological processes implicated in neurodegenerative diseases.
Our research programme is exploring the potential application of these botanical therapeutics across a range of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Preclinical investigations have demonstrated promising effects on neuroinflammatory pathways, oxidative stress regulation, neuronal protection, and motor function, providing a strong scientific foundation for continued translational development.
Building upon these encouraging findings, NatureCeuticals is advancing its neuroscience programme toward clinical evaluation, with future studies planned to investigate the safety and efficacy of its proprietary botanical formulations in patients with neurodegenerative diseases.
Through rigorous scientific research and strategic collaborations with leading academic and clinical partners, NatureCeuticals is committed to developing evidence-based botanical medicines that have the potential to improve neurological health, preserve cognitive function, and enhance the quality of life of patients living with chronic neurodegenerative disorders.
Advancing Botanical Therapeutics for Neurodegenerative Diseases
NatureCeuticals is actively investigating the therapeutic potential of its proprietary botanical platform for the prevention and management of neurodegenerative disorders. Our neuroscience research integrates molecular pharmacology, pharmaceutical sciences, and translational medicine to develop innovative botanical therapeutics targeting the complex biological mechanisms underlying progressive neurological diseases.
Extensive preclinical studies have evaluated standardized Orthosiphon stamineus formulations rich in bioactive phytochemicals, including rosmarinic acid and sinensetin. These compounds have demonstrated potent antioxidant, anti-inflammatory, and neuroprotective activities in experimental models, supporting their potential role in reducing oxidative stress, neuroinflammation, and neuronal injury—key pathological processes implicated in neurodegenerative diseases.
Our research programme is exploring the potential application of these botanical therapeutics across a range of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Preclinical investigations have demonstrated promising effects on neuroinflammatory pathways, oxidative stress regulation, neuronal protection, and motor function, providing a strong scientific foundation for continued translational development.
Building upon these encouraging findings, NatureCeuticals is advancing its neuroscience programme toward clinical evaluation, with future studies planned to investigate the safety and efficacy of its proprietary botanical formulations in patients with neurodegenerative diseases.
Through rigorous scientific research and strategic collaborations with leading academic and clinical partners, NatureCeuticals is committed to developing evidence-based botanical medicines that have the potential to improve neurological health, preserve cognitive function, and enhance the quality of life of patients living with chronic neurodegenerative disorders.
OUR RESEARCH PARTNERS
